These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32643975)

  • 21. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
    Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
    Nwanegbo EC; Romanowski EG; Gordon YJ; Gambotto A
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4171-6. PubMed ID: 17724203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenoviral keratoconjunctivitis associated with stromal oedema and keratic precipitates.
    Tsagkataki M; Trainor E; Kaye LC; Hopkins MJ; Kaye SB
    Clin Exp Ophthalmol; 2013; 41(7):715-6. PubMed ID: 23336741
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.
    Shorter E; Whiteside M; Harthan J; Margolis MS; Hartwick AT; Johnson S; Migneco M; Morettin C; Olson CK; Huecker J; Than T; Gordon MO
    Ocul Surf; 2019 Oct; 17(4):828-832. PubMed ID: 31401340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis.
    Bhargava R; Kumar P
    Indian J Ophthalmol; 2019 May; 67(5):594-598. PubMed ID: 31007215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of adenovirus amplified detection of immunochromatographic test using tears including conjunctival exudate in patients with adenoviral keratoconjunctivitis.
    Migita H; Ueno T; Tsukahara-Kawamura T; Saeki Y; Hanaoka N; Fujimoto T; Uchio E
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):815-820. PubMed ID: 30826875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.
    Levinger E; Slomovic A; Sansanayudh W; Bahar I; Slomovic AR
    Cornea; 2010 Jun; 29(6):638-40. PubMed ID: 20458220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.
    Okumus S; Coskun E; Tatar MG; Kaydu E; Yayuspayi R; Comez A; Erbagci I; Gurler B
    BMC Ophthalmol; 2012 Aug; 12():42. PubMed ID: 22900547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study.
    Trinavarat A; Atchaneeyasakul LO
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):53-8. PubMed ID: 21916618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Epidemic keratoconjunctivitis: treatment results during an epidemic].
    Hutter H
    Klin Monbl Augenheilkd; 1990 Sep; 197(3):214-7. PubMed ID: 1701507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Locferon: new eyedrops for treatment eye adenoviral diseases].
    Maĭchuk IuF; Iani EV
    Vestn Oftalmol; 1999; 115(2):32-3. PubMed ID: 10377873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.
    Levinger E; Trivizki O; Shachar Y; Levinger S; Verssano D
    Graefes Arch Clin Exp Ophthalmol; 2014 May; 252(5):811-6. PubMed ID: 24696044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phlyctenular Keratoconjunctivitis in a Patient With COVID-19 Infection.
    Eleiwa TK; Elmaghrabi A; Helal HG; Abdelrahman SN; ElSheikh RH; Elhusseiny AM
    Cornea; 2021 Nov; 40(11):1502-1504. PubMed ID: 34320598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Personal experience with the use of Betadine gtt. in the treatment of epidemic viral keratoconjunctivitis].
    Pernický J
    Cesk Oftalmol; 1994 Oct; 50(5):323-4. PubMed ID: 7805123
    [No Abstract]   [Full Text] [Related]  

  • 35. Adenoviral keratoconjunctivitis in a tertiary care eye clinic.
    Butt AL; Chodosh J
    Cornea; 2006 Feb; 25(2):199-202. PubMed ID: 16371782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral steroid therapy as an adjuvant treatment for severe epidemic keratoconjunctivitis in patients younger than 3 years.
    Kim SY; Chung YK; Lee YC; Kim SY
    Cornea; 2015 Feb; 34(2):182-7. PubMed ID: 25522221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of Bandage Contact Lenses in Adenoviral Keratoconjunctivitis.
    Uçakhan Ö; Yanik Ö
    Eye Contact Lens; 2016 Nov; 42(6):388-391. PubMed ID: 26671622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
    Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
    Am J Ophthalmol; 2020 Jul; 215():56-65. PubMed ID: 32222367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.
    Asena L; Şıngar Özdemir E; Burcu A; Ercan E; Çolak M; Altınörs DD
    Eye (Lond); 2017 May; 31(5):781-787. PubMed ID: 28157224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of Outcomes of Adenoviral Keratoconjunctivitis.
    Lee CS; Lee AY; Akileswaran L; Stroman D; Najafi-Tagol K; Kleiboeker S; Chodosh J; Magaret A; Wald A; Van Gelder RN;
    Ophthalmology; 2018 Sep; 125(9):1344-1353. PubMed ID: 29602567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.